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Abstract: Cytidine 51-diphosphocholine or citicoline is an endogenous compound that acts in the
biosynthetic pathway of phospholipids of cell membranes, particularly phosphatidylcholine, and
it is able to increase neurotrasmitters levels in the central nervous system. Citicoline has shown
positive effects in Parkinson’s disease and Alzheimer’s disease, as well as in amblyopia. Glaucoma
is a neurodegenerative disease currently considered a disease involving ocular and visual brain
structures. Neuroprotection has been proposed as a valid therapeutic option for those patients
progressing despite a well-controlled intraocular pressure, the main risk factor for the progression of
the disease. The aim of this review is to critically summarize the current evidence about the effect of
citicoline in glaucoma.
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1. Introduction
Cytidine 51-Diphosphocholine (Citicoline): Mechanism of Action
Cytidine 51-diphosphocholine, known as citicoline, is a naturally occurring endogenous
compound. It is a mononucleotide composed of ribose, cytosine, pyrophosphate and choline (Figure 1)
and it is an intermediate in the synthesis of membrane phospholipids such as phosphatidylcholine [1–3].
It has been reported that changes of citicoline concentration modify the synthesis of 80% of central
nervous system (CNS) phospholipids.
Choline precursors are exogenous molecules that are converted in the body. Oral doses of citicoline
are in fact absorbed rapidly and then hydrolysed in the intestinal wall and liver to choline and cytidine.
Both choline and cytidine enter the systemic circulation, cross the blood–brain barrier, and combine
to form citicoline within the CNS where it increases the biosynthesis of phospholipids [4]. Citicoline
stimulates phosphatidylcholine synthesis, attenuates Free Fatty Acids (FFAs) release. Furthermore,
citicoline re-establishes levels of cardiolipin phospholipid component of the inner mitochondrial
membrane (structural action) [5].
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Figure 1. Chemical structure of Cytidine 5′-Diphosphocholine or citicoline [4]. 
Citicoline also increases some brain neurotransmitters such as dopamine (via enhancing tyrosine 
hydroxylase activity and inhibiting dopamine reuptake), noradrenaline, serotonin and serves as a 
choline donor in the biosynthesis of acetylcholine (functional action) [6]. 
Recently, citicoline has been studied in a murine model of experimental autoimmune 
encephalomyelitis and in the cuprizone model of toxic induced demyelination where promoted 
remyelination by increasing the number of oligodendrocyte precursor cell in vivo and in vitro, 
suggesting a new mechanism of action of this molecule with potential clinical impact in multiple 
sclerosis patients [7]. 
Citicoline can be considered a non-toxic molecule. In preclinical studies, none of the animals 
died after taking the maximum oral dose. Toxicity studies of oral citicoline did not show any toxic 
effects when it was administered in rodents and dogs whether for 30 days or for six months. Blood 
chemistry, organ histology, neurological or urinary parameters did not change [8]. 
In many clinical trials no serious adverse events have been provided, while after few days of 
treatment sporadic nonserious adverse effects included gastrointestinal discomfort, uneasiness, and 
irritability. 
A large study analyzed the safety profile of citicoline in 2817 patients and only 5% of patients 
reported adverse effects related to the therapy and no patients needed to stop the therapy [9]. Those 
patients were affected with Alzheimer’s disease (AD) and vascular dementia and were treated for 2–
9 weeks. 
Because of all these properties, the use of citicoline has been studied as a promising therapeutic 
strategy in brain ischemia, AD and Parkinson’s disease (PD) and in ocular diseases such as 
amblyopia, non-arteritic ischemic optic neuropathy and glaucoma [10–30]. 
2. Evidence on the Effects of Citicoline in Ocular and Non-Ocular Neurological Conditions 
2.1. Citicoline and Brain Ischemia 
During brain ischemia and trauma there is an increase of activation of phospolipases A2 with 
accumulation of FFAs and arachidonic acid [12]. 
A large number of experimental studies have explored the protective effects of citicoline in 
stroke models. At the experimental level, citicoline has been reported to reduce infarct volume and 
brain edema. This led to an improvement of neurologic deficits either when citicoline was used as a 
single therapy or in combination with other agents [13]. 
Clinical stroke trials reported the effectiveness of citicoline when used soon after the ischemia, 
as demonstrated by improvements in level of consciousness and modified Rankin score (mRs). 
Nevertheless, since different sample sizes, multiple doses and several outcome endpoints were used, 
it became difficult to reach substantial conclusions. 
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hydroxylase activity and inhibiting dopamine reuptake), noradrenaline, serotonin and serves as a
choline donor in the biosynthesis of acetylcholine (functional action) [6].
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suggesting a new mechanism of action of this molecule with potential clinical impact in multiple
sclerosis patients [7].
Citicoline can be considered a non-toxic molecule. In preclinical studies, none of the animals died
after taking the maximum oral dose. Toxicity studies of oral citicoline did not show any toxic effects
when it was administered in rodents and dogs whether for 30 days or for six months. Blood chemistry,
organ histology, neurological or urinary parameters did not change [8].
In m ny clinical trials no serious adverse events have been provided, while after few days
of treatment sporadic nonserious adverse effects included gastrointestinal discomfort, uneasiness,
and irritability.
A large study analyzed the safety profile of citicoline in 2817 patients and only 5% of patients
reported adverse effects related to the therapy and no patients needed to stop the therapy [9]. Those
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Because of all these properties, the use of citicoline has been studied as a promising therapeutic
strategy in brain ischemia, AD and Parkinson’s disease (PD) and in ocular diseases such as amblyopia,
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2.1. Citicoline and Brain Ischemia
Duri g brain ischemia d trauma there is an in rease of activation of phospolipases A2 with
accumulation of FFAs and arach donic acid [12].
A large number of experimental studies have explored the protective effects of citicoline in stroke
models. At the experimental level, citicoline has been reported to reduce infarct volume and brain
edema. This led to an improvement of neurologic deficits either when citicoline was used as a single
therapy or in combination with other agents [13].
Clinical stroke trials reported the effectiveness of citicoline when used soon after the ischemia,
as demonstrated by improvements in level of consciousness and modified Rankin score (mRs).
Nevertheless, since different sample sizes, multiple doses and several outcome endpoints were used, it
became difficult to reach substantial conclusions.
In 2012 the results of an international, randomized, multicenter, placebo-controlled study (the
ICTUS trial) initiated to confirm the efficacy of citicoline for the treatment of ischemic stroke in a larger
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trial, were published on the Lancet. In the study 2298 patients with moderate-to-severe acute ischemic
stroke were randomly assigned in a 1:1 ratio to get citicoline or placebo within 24 h after the onset of
symptoms (1000 mg every 12 h intravenously during the first three days and later orally 500 mg two
times per day) for a total of six weeks. The primary outcome was recovery after 90 days measured by
the results of three tests: National Institutes of Health Stroke Scale (NHSS), mRs and Barthel Index.
The NHHS is a 15-item scale that measures the level of neurological impairment, the mRs is a measure
of disability and Barthel index assesses the ability of patients to practice daily activities [14].
The results showed that global recovery was similar in both groups (odds ratio 1.03, 95% CI
0.86–1.25; p = 0.364) and the authors concluded that under the clinical conditions of the ICTUS trial,
citicoline was not effective [14].
Recently, it has been highlighted that a large proportion of patients in the ICTUS trial has been treated
with intra-venous recombinant tissue plasminogen activator (rt-PA) and this might have interfered with
the potential beneficial effects of citicoline. Rt-PA in fact might have re-established blood flow in the
penumbra region, and therefore, the benefit that citicoline could provide was altered demonstrating the
difficulty of improving the outcome on top of the effect of rt-PA, caused by a ceiling effect of thrombolysis.
The authors then concluded that the results of the ICTUS suggested that citicoline might be useful in
those patients with acute ischemic stroke who were not treated with rt-PA [15].
2.2. Citicoline and Alzheimer’s Disease (AD)
Citicoline may hinder the deposition of beta-amyloid, a pivotal neurotoxic protein in the
pathophysiology of AD [16].
It has been proposed an interaction between amyloid peptiteds formation and membrane
phospholipid breakdown [17–19].
Amyloid peptides are able to activate phospholipase A2 [17]; therefore, formation of amyloid
peptide is expected to accelerate membrane breakdown [18,19].
Alvarez et al. [20] have investigated the efficacy and safety of the treatment with citicoline versus
placebo in 30 patients with AD after 12 weeks of treatment. It was a double-blind placebo-controlled
study and compared to placebo, citicoline improved cognitive performance in AD patients, and this
improvement was more pronounced in patients with mild dementia. Those patients showed also an
increase in the percentage of brain bioelectrical activity and in cerebral blood flow velocity.
Franco et al. [21] confirmed an improvement in mental performance and brain electrical activity
data correlated with cognitive parameters in patients with early-onset AD after one month of treatment
with CDP-choline.
Furthermore, a recent Cochrane systematic review on the role of citicoline in cognitive impairment
identified 14 trials enrolling 1051 patients with vascular cognitive impairment, vascular dementia or
senile dementia (mild to moderate) and concluded that there was some evidence of a positive effect of
the molecule upon memory, behavior, and global functioning, despite not on attention [22].
2.3. Citicoline and Parkinson’s Disease (PD)
Many authors have investigated the role of citicoline in PD [23–25] postulating that stimulation
of the dopaminergic system induced by citicoline is at the basis of the improvement of neurological
symptoms in PD.
Agnoli et al. [23] administered citicoline to PD patients in a double-blind cross-over controlled
study. All patients were already treated with L-dopa + dopa decarboxylase inhibitor. Citicoline
treatment determined a significant improvement of rigidity and bradykinesia and a less important
improvement of tremor.
Besides, citicoline could be used to decrease the incidence of side effects and slow down the loss
of efficacy of levodopa in the long-term treatment. In a study by Eberhardt R et al. [24], 85 patients with
an established diagnosis of primary PD were randomly assigned to receive 381 mg of levodopa daily
plus 1200 mg of citicoline daily or half dose of daily levodopa (mean, 196 mg daily) plus citicoline.
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The results of the Webster Rating Scale, indicating the severity of the disease and the clinical
impairment, and results of other tests evaluating the ability to walk, draw and write and a global
clinical evaluation were performed before and after four weeks of treatment: no significant differences
were found between the two study groups. Improvements of tests’ scores were shown in more patients
who received half their levodopa dose plus citicoline than in those who continued to receive their usual
levodopa dose plus the citicoline. Therefore, the authors concluded that citicoline could be used to
decrease the incidence the side effects of levodopa and to delay the loss of its efficacy in the long-term
treatment [25].
2.4. Citicoline in Amblyopia and Non-Arteritic Ischaemic Optic Neuropathy
The stimulation of the dopaminergic system by citicoline may be also responsible of the
improvement of retinal and postretinal visual pathways in amblyopia.
Citicoline has been shown to enhance visual acuity, contrast sensitivity, visual evoked responses
and the effect of part-time occlusion, at least temporarily, in amblyopic patients over the plastic period
of the visual system.
Campos et al. [26] compared the effect of orally administered citicoline on visual function in
addition to patching for the treatment of amblyopia in children after 30-day treatment. In an open-label
parallel group study sixty-one participants suffering from anisometropic or strabismic amblyopia,
citicoline was not found to be more effective than patching alone, but citicoline was able to stabilize
the effect obtained during the treatment period. In fact, while after 90 days subjects treated only with
patching showed a decrease in visual acuity, those receiving citicoline plus patching appeared to keep
their visual acuity [27,28].
Porciatti et al. [29] measured visual acuity, contrast sensitivity and Visual Evoked Potential (VEP)
in a group of 10 amblyopic subjects before 15 days of intramuscular treatment with citicoline, and
the day after the end of treatment. On average, after treatment, visual acuity improved in both eyes,
1.4–1.5 lines in the amblyopic eyes and 0.4 lines in the control eyes. Contrast sensitivity improved
in both dominant and amblyopic eyes of about 3 dB. VEPs increased in amplitude (about 30%) and
advanced in phase (about 0.2 pi rad).
In 2008, Parisi et al. [30] evaluated visual function before and after treatment with oral citicoline
for 60 days in patients with non-arteritic ischaemic optic neuropathy. At the end of treatment,
patients showed an improvement (p < 0.01) of Pattern Electroretinogram (PERG), VEP parameters and
visual acuity, compared to pre-treatment values. After wash out, functional improvements persisted
compared to baseline. The age-matched control group did not show any improvement.
3. Glaucoma as a Central Nervous System (CNS) Disease
Glaucoma is a group of optic neuropathies in which the death of retinal ganglion cells (RGCs) leads
to an abnormal increase of the optic nerve head (ONH) excavation and a correspondent permanent
impairment of visual field [31]. It represents the second cause of irreversible blindness in the world
and 111.8 million of people are estimated to be affected in 2040 [32]. An intraocular pressure (IOP)
elevated beyond the susceptibility of retinal structure, is considered the most important risk factor for
developing glaucoma, and several randomized clinical trials have shown that untreated patients with
elevated IOP are more likely to develop glaucomatous damages than those receiving treatment [33–35].
Despite lowering IOP by medical therapy, laser or surgical procedures is the only approach
generally recognized, up-to-date there is a body of evidence that suggests IOP is not the unique risk
factor involved in the pathogenesis of the disease.
Elevated IOP is not always associated with glaucoma considering that a certain amount of subjects
with an IOP beyond normal statistical limits will never develop the disease [36]. On the other hand,
hypotensive therapy alone is not always sufficient in preserving visual function, considering that in
some cases, despite a well-controlled IOP the disease continue to progress [37].
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We can assume that in such patients, a more consistent IOP lowering would be beneficial and
needed, but it is also reasonable to hypothesize that other factors rather than IOP are involved.
Glaucoma was originally identified as a disease associated with IOP and for long-time elevated
IOP was considered synonymous to glaucoma. To date, IOP is still managed as a the main risk factor
but current glaucoma definition is focused on physiopathological features of the disease [37,38]: a
progressive optic neuropathy, which primarily involves RGCs, and concurrently alters the whole visual
pathways running from the eye to visual cortex.
Gupta et al. [39] in a 2006 study have firstly demonstrated the presence of degenerative changes
at lateral geniculate nucleus (LGN) and visual cortex in a human glaucoma case. RGCs death was
associated with atrophy and loss of their target neurons at the level of LGN and visual cortex thickness
was reduced compared with controls. These results were in accordance with previous histological
evidence from experimental animal model studies [40,41].
Therefore, the eye could be viewed as a part of the CNS and correspondingly, glaucoma could be
considered a brain neurodegenerative disease, as firstly suggested by Shumer et al. [42] in a 1994 study.
Moreover, neurological progressive diseases, such as AD, amyotrophic lateral sclerosis and PD, exhibit
several common mechanisms of cell death with glaucoma.
The paradigm of glaucoma like as a neurological disorder, associated with evidences showing
how insufficient is the therapeutic approach based on the IOP lowering therapy alone, suggests that
neuroprotection may play a therapeutic role (alternative or adjuvant) in glaucoma.
4. Glaucoma Physiopathology and Neuroprotection
Even though pathological changes in glaucoma occur along the whole visual pathway, the death
of the RGCs is the crucial pathophysiological event [43,44].
Moreover, the damage of RGCs is not limited to the neurons primary insulted, as a matter of fact
a secondary degeneration may also involve the neighboring neurons localized closely to those initially
damaged, as a consequence of extracellular environment changes. Degeneration also occurs in the
target neurons by a process called trans-synaptic degeneration. Such forms of slow and progressive
secondary or trans-synaptic degeneration, may explain why lowering IOP is not always enough to
halt the progression of the disease in glaucoma patients.
Whatever the primary insult is, the final death pathway of RGC is a programmed cell death
process called apoptosis [45,46].
Neuroprotection is a therapeutic approach aimed to prevent, hamper, delay or reduce neuronal
cell death by directly targeting neurons [47]. Differently from IOP lowering strategy, which prevents
RGCs death by reducing primary insult (indirect neuroprotection), neuroprotective agents aim to
influence the biological properties of the neurons that are directly involved in cell death pathway. Such
form of “cell protection” could be effective whatever the primary insult is located, and even when
the primary insult itself is not completely or partially known, because it is directed toward the final
common mechanism involved in RGCs death.
RGCs survival is believed to be dependent from a balance between survival signals and neurotoxic
stimuli. Apoptosis is the consequence of the lost of such a balance, which is shifted in favor of
neurotoxic stimuli. Neuroprotective agents can act either by increasing the survival stimuli and/or
by hindering the neurotoxic signal, and more in general by targeting the mechanisms that trigger the
apoptotic cascade [48].
Deprivation of neurotrophins is one of the mechanisms involved [49]. In glaucoma acute or
chronic elevation of IOP can lead to a blockade of the axonal retrograde transport of neurotrophin from
the superior colliculus to the ONH [50,51]. Neurotrophic factor (such as brain derived neurotrophic
factor, BDNF) are essential for cell survival and growth and apoptosis might be a consequence of
their deprivation. A neuroprotective approach relying on the increase of endogenous expression or
providing exogenous intake of neurotrophins, has been assessed in several studies [52,53].
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Another mechanism largely investigated is the glutamate-mediated excitotoxicity. Cells that start
undergoing apoptosis usually release a large amount of glutamate in the extracellular area, which
increases the income of Ca2+ in the neighboring cells, leading to secondary degeneration [54]. Blocking
the glutamate excitotoxicity cascade, by interfering with its release or blocking its receptor, represents
a potential neuroprotective strategy [55].
Protein misfolding, oxidative stress, mithocondrial dysfunction, activation of astrocytes and
microglia are further mechanisms suggested to be involved as triggers of the apoptotic cascade and
potential targets for neuroprotection. Despite none of them have achieved a predominant role, a
large amount of pre-clinical studies have shown promising results on the effectiveness of several
neuroprotectant molecules in reducing the loss of RGCs in glaucoma experimental models [56,57].
For example, recent studies have proposed methylene blue as a neuroprotectant. This agent might
interfere with the mitochondrial electron transport complex reducing production of superoxide and
free radicals in response to the stress induced by glutamate [58]. In addition, the 17β-estradiol (E2) has
been investigated to prevent RGC death in a glaucoma model of elevated IOP in rats. After treatment
with E2 eye drops the number of apoptotic cells in the RGC layers was significantly decreased but
systemic side effects could not be prevented [59].
Unfortunately, translation from pre-clinical studies to randomized clinical trials is still lacking,
and up-to-now only two neuroprotective drugs are currently approved by the Food and Drugs
Administration: memantine for AD (moderate to advance stages) [60] and riluzole for lateral
amyotrophic disease [61]. For glaucoma, instead, no neuroprotectans have been registered so far.
5. Role of Citicoline in Glaucoma: Current Evidence
5.1. Experimental Studies on Citicoline as a Neuroprotectant
Some experimental studies have confirmed the protective role of citicoline on RGCs and its
neuromodulator effect (Table 1).
In 2002 Rejadak et al. [62] showed that citicoline influences retinal catecholamine levels in adult
male Albino rabbits. Six animals were injected intraperitoneally with 50 mg/kg of citicoline twice
daily for seven days. The control group (four animals) received vehicle injections according to the
same schedule. At the end of the treatment period animals were sacrificed and retinal catecholamine
concentrations were measured using HPLC. Dopamine levels were found to be higher in animal
treated with citicoline compared to those treated with vehicle only, while adrenaline concentration
was slightly higher and noradrenalin remained unmodified.
Oshitari et al. [63] aimed to study the clear effect of citicoline on damaged RGCs. They carried
out tissue culture of mouse retinal explants, and investigated the effect of citicoline on damaged
RGCs by quantitative analysis of TdT-dUTP terminal nick-end labeling (TUNEL) positivity in the
ganglion cell layer (GCL) and the assessment of the amount of regenerating neurites. The proportion of
TUNEL-positive cells in the GCL was very low in mouse retina treated with 0.1–10 mmol/L compared
with those of the control (p < 0.05).
Authors postulated an antiapoptotic effect of citicoline in mitochondria-dependent cell death
mechanism, and its ability in supporting axon regeneration.
The antiapoptotic effect of citicoline was also evaluated in the study by Shuettauf et al. [64].
Adult rats were divided in four groups and treated with vehicle only, with citicoline (1 g/kg the first
seven days and then 300 mg/kg), with lithium (30 mg/kg) or with a mixture of citicoline and lithium.
Intraperitoneal injections of drugs were made once a day, starting one day prior to partial optic nerve
crush, up to the day of the tissue sampling. The density of RGC connected with superior colliculus was
higher in animals treated with citicoline compared to those treated with vehicle one week and three
weeks after the crush. The expression of the antiapoptotic protein Bcl-2 was recorded in the lithium
group, in the citicoline group and in the group treated with both drugs [64].
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Table 1. Experimental studies.
Authors Year Study Design Animal Citicoline Concentration Citicoline Administration Outcomes
Rejdak R et al. [62] 2002 case-control Albino rabbits 50 mg/kg/twice day Intraperitoneal injection Retinal catecholamine levels
Park CH et al. [65] 2005 case-control Spraue-Dawley rats 50 mg¨kg´1 Intraperitoneal injection Thickness of retinal layers andexpression of ChAT and TH
Schuettauf F et al. [64] 2006 case-control Rats 1 g/kg/daily and300 mg/kg/daily Intraperitomeal injection
Retinal ganglion cells density
and expression of the
antiapoptotic protein Bcl-2
Oshitari T et al. [63]. 2010 case-control Cultures from Spraue-Dawley rats 1 µM Added to high glucose medium inretinal culture
Apoptosis evaluation by TUNEL
assay and Caspase-3 and
Caspase-9 activity
Matteucci A et al. [66]. 2014 case-control Cultures from embryonic rat retina 10, 100 and 1000 µM
Treated for 96 h and 24 h before
glutamate-induced excitotoxic insult
and high glucose-promoted neuronal
cell damage
Apoptosis evaluation by TUNEL
assay and caspase activation
Summary of experimental studies evaluating the effect of citicoline on retinal ganglion cells survival.
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The neuromodulator effect of citicoline was observed in a model of Kainic acid (KA)-induced
retinal damage, using choline acetyltransferase (ChAT) and tyrosine hydroxylase (TH) [65]. One group
of male rats were injected with KA in the vitreous space, one group was injected intraperitoneally
with citicoline (500 mg¨kg´1) twice daily for one, three and seven days after KA-injection and one
group served as control group. In KA treated animals the entire retinal thickness gradually decreased
compared with the control retinas, while in the citicoline treated animals there was a significant
attenuated reduction. Furthermore, the ChAT immunoreactivity was significantly protected by the
treatment with citicoline, which prevented the complete disappearance of TH immunoreactivities.
Since KA is an analogue of glutamate, authors concluded that citicoline might have the neuroprotective
action in glutamate-mediated cell death [65].
In addition, the safety characteristic of the drug has been confirmed in in vitro models of
retinal neurodegeneration.
In 2014, Matteucci et al. [66] investigated the effect of citicoline (10, 100 and 1000 µM) on cell
damage in cultures from embryonic rat retina composed of mixed neuronal and glial cell population.
Results confirmed that citicoline does not modify the rate of apoptotic cells, evaluated by TUNEL
positivity and caspase activation and does not change cell composition. Then, authors set up models
of both glutamate-induced excitotoxicity, considered of pathophysiological relevance in glaucoma,
and high glucose-promoted neuronal cell damage. Primary retinal cultures were treated with 100 µM
citicoline 24 h before excitotoxic insult, induced with exposure to 100 µM glutamate for 25 min.
Controls included retinal cultures treated with iso-osmolar mannitol. The apoptotic rate evaluated by
TUNEL assay and synaptic damage in glutamate-treated cells was significantly reduced by treatment
with citicoline, compared to controls. The cell culture model used in this study allowed the evaluation
of the effects of citicoline on different cell types and strengthened the neuroprotective effect of the
intact citicoline. In fact, in in vitro system the drug was not metabolized and this evidenced why
liposomal preparations of citicoline, where the drug is delivered as intact molecule, are more active
than parenteral administration, which are more susceptible to transformation in the two metabolites
choline and cytidine.
Recently, the neuroprotective effect of citicoline has been demonstrated on retinal nerve fibers in
hyperglycemia conditions. In a mouse model of diabetes it has been shown that citicoline eye drops
counteracts retinal nerve fibers layer thinning [67]. Results are in agreement with those of a previous
study investigating the effect of BDNF, neurotrophin-4 (NT-4), and citicoline on neuronal apoptosis
and neurite regeneration in cultured rat retinas exposed to high glucose. The authors, in fact, observed
a decreased number of apoptotic cells with suppression of caspase-9 and caspase-3 activities [68].
5.2. Clinical Studies
The neurotrophic effect of citicoline in glaucoma management has been clinically investigated
from long time (Table 2).
Pecori Giraldi et al. [69] in 1989 reported positive results obtained on visual fields of patients
affected with open angle glaucoma after intramuscular injection of citicoline. The drug was given
at the dose of 1 g for 10 consecutive days, and patients were examined at baseline and after 15 days
and three months. The authors found an improvement of visual field in 75% of the 34 examined eyes,
based on the reduction in the scotomatous area (computerized central perimetry) and mean defect.
Visual field improvement remained stable for further three months with lack of side-effects and the
same favorable results were obtained when the treatment was repeated.
Ten years later, the same authors reported the results from a prospective study on 23 eyes of
23 glaucoma patients with early or moderate perimetric defects with 10 year follow up [70]. Eleven
patients were treated with citicoline administered intramuscularly associated with topical hypotensive
treatment (1 g for 15 days repeated every 6 months), while 12 patients received topical hypotensive
treatment alone. The outcome measure was visual field progression evaluated by an increase of the
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non-perception area (NPA) >500 mm2. Citicoline-treated patients exhibited a significant improvement
of retinal sensitivity (NPA reduction) at one-year follow up, and remained stable after nine years.
The authors related these results to those obtained from neurological studies on the use of
citicoline in ischemic, traumatic or degenerative events of the CNS and its hemodynamic properties,
able to increase the cerebral and ocular blood flows.
To better understand which structures of the visual system may selectively participate in the
improvement of damaged visual field, Parisi et al. [71], in 1999, evaluated the effect of citicoline on
retinal function and on cortical responses in patients with glaucoma using electrofunctional tests (VEP
and PERG). Forty patients with early to moderate glaucoma and well-controlled IOP were randomly
divided into two age-matched groups: 25 were treated with citicoline plus hypotensive treatment
(GC) and 15 were treated with placebo (GP) plus hypotensive treatment. A daily intramuscular dose
of 1 g citicoline or placebo was prescribed for 60 days followed by 120 days of washout. Later, GC
patients were divided in two age-matched groups: in 10 patients (GC1) the washout was prolonged
for a further 120 days, while in 15 patients (GC2) a second 60-day period of citicoline treatment was
followed by a second 120-day period of washout. The GP group showed similar parameters in all
tests performed. In GC group, treatment with citicoline induced a significant improvement of VEP
and PERG parameters that was treatment-dependent: at day 300 GC1 patients presented an additional
worsening in VEP and PERG parameters and no differences with respect to baseline and with respect
to GP patients, while in GC2 a second 60 days period of citicoline treatment induced an additional
improvement of VEP and PERG parameters still maintained after the second washout.
In 2005, Parisi [72] reported data obtained from 12 GP and 12 GC patients during 14 additional
periods of the schedule treatment (two months treatment with citicoline plus hypotensive therapy, four
months washout from citicoline) for a total of 96 months (eight years). They wanted to evaluate the
long-term effect of citicoline treatment, assessing the differences observed at the end of each period of
follow up in comparison with baseline conditions. The additional periods of citicoline treatment in GC
patients during the subsequent months induced a greater improvement of VEP and PERG parameters
as compared with pre-treatment conditions, and when compared to GP patients. Furthermore, at the
end of the follow up an increase in visual field mean deviation (MD) when compared to baseline values
was also observed in all GC patients. This increase was significantly related to electrofunctional results.
They concluded that previously reported changes of perimetric conditions might be tributable
to an improvement of both retinal and post-retinal structures induced by citicoline treatment. Since
citicoline is able to increase dopamine levels in CNS. The authors suggested that in both VEP and PERG
improvement a dopaminergic-like activity could be suggested. Dopamine is one of the most important
neurotrasmitter involved in retinal and post retinal visual pathways and levodopa was found to
increase retinal functions in humans treated with this substance [23–25]. Similar results were observed
in amblyopic patients by the improvement of visual acuity after treatment with citicoline [26–29].
All these studies refer to citicoline treatment administered by intramuscular injection. Oral
administration of citicoline was thereafter also investigated.
In particular, the first results were obtained from Rejadak et al. [73] in 2003. Eleven glaucoma
patients were treated with citicoline tablets, each containing 0.5 g of the active ingredient. These tablets
were prepared by the local hospital pharmacy. After the first VEP recording, the patients were supplied
with 28 citicoline tablets (one tablet every 12 h for 14 days). After a two-week break, they were supplied
with a second set of 28 citicoline tablets. The second VEP measurement was taken two weeks after the
end of the second two-week treatment course. There was a significant positive correlation between the
pretreatment VEP P100 latency values and the decrease of latency observed following treatment, and a
significant difference in the pre-treatment VEP latencies between the responding and non-responding
eyes. The authors concluded that oral citicoline treatment might normalize VEPs in glaucoma patients.
In 2008 Parisi et al. [74] studied the effect of oral suspension (1600 mg/die) or intramuscular (1 g/die)
citicoline on visual pathways function and conduction of glaucoma patients with moderate visual defects.
Three groups of 20 patients under hypotensive therapy were followed for one year: Group 1 did not take
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citicoline, Group 2 took intramuscular citicoline and Group 3 took oral citicoline. The pharmacological
treatment was performed for two months followed by four months of washout and the scheme was
repeated for two times. Improvement of retinal function evaluated by PERG and neural conduction
along visual pathways evaluated by VEP were observed after both oral and intramuscular treatment
with citicoline. No differences were found between intramuscular and oral administration, and adverse
side effects were not reported by any of the patients enrolled in the study. Partial regression was detected
after washout.
In 2013, Ottobelli et al. [75] reported results from a multicentric study on the effect of citicoline
oral solution on the rate of progression of visual field in patients with progressive glaucoma. Forty-one
patients with a disease progression of at least ´1 dB/year at MD for at least three years before entering
the study despite controlled IOP completed the study. They received citicoline oral solution for two years
(one vial, 500 mg per day for a period of four months and stopped for two months) and were followed
up with four visual field tests per year for two years. From the first cycle of treatment with citicoline, the
mean rate of progression significantly reduced to ´0.15 (˘0.3) dB/year at the end of the study (Figure 2).
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Figure 2. Rates of progression (RoP) during the study. B = Baseline. 2-B: two years before baseline.
(Figure adapted from Reference n [75]).
Furthermore, IOP was approximately 1 mmHg lower during the follow up as compared to
baseline, and patients with IOP higher than 15 mmHg had faster rate of progression (´0.25 dB/year)
than patients with IOP lower than 15 mmHg (´0.05 dB/year). Citicoline and mean IOP were the only
variables that were significantly associated with MD changes. This study confirmed the lack of side
effects associated with citicoline even administered as oral solution.
Moreover, previous studies demonstrated that the oral solution has a good bioavailability and
can reach the same therapeutic efficacy with respect to the parenteral administration (intravenous and
intramuscular) [76,77].
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Table 2. Clinical studies.
Authors Year Study Design Study Population Adm Dosage Schedule of Treatment Follow-up Outcomes
Pecori Giraldi et al. [69] 1989 cohort Open Angle Glaucoma(OAG) IM 1 g/day 10 days 3 months
Reduction in the scotomatous area
(computerized central perimetry) and
decrease in mean defect
(automated perimetry)
Parisi V et al. [71] 1999 case-control
OAG
´3 dB > Mean Deviation
(MD) <´6 dB
IM 1 g/day 60 days 120 days ofwashout (2 cycles) 360 days
Visual Evoked Potential (VEP) and Pattern
Electroretinogram (PERG) parameters
Virno M et al. [70] 2000 case-control OAG IM 1 g/day 15 days 180 days ofwashout (20 cycles) 10 years
Visual field worsening (increase of
non-perception area >500 mm2)
Rejdak et al. [73] 2003 cohort OAG Oral 1 g/day 14 days 2 days ofwashout (2 cycles) 56 days VEP parameters
Parisi V [72] 2005 case-control OAG´3 dB > MD <´6 dB IM 1 g/day
60 days 120 days of
washout (14 cycles) 8 years VEP and PERG parameters
Parisi V et al. [74] 2008 case-control OAG´2 dB > MD <´14 dB IM Oral
1 g/day
1600 mg/day
60 days 120 days of
washout (2 cycles) 360 days VEP and PERG parameters
Ottobelli L et al. [75] 2013 retrospective cohort progressing OAG Oral(solution) 500 mg/day
120 days 60 days of
washout (4 cycles) 2 years Rate of visual field progression
Roberti et al. [78] 2014 experimental and clinical(case-control)
OAG
´3 dB > MD <´12 dB
Topic
(eye drops) 3 drops/day 60 days 90 days VEP and PERG parameters
Parisi V et al. [79] 2015 case-control OAGMD >´10 dB
Topic
(eye drops) 3 drops/day
120 days 60 days
of washout 180 days VEP and PERG parameters
Summary of clinical studies evaluating the effect of citicoline in glaucoma patients by means of visual field and electrophysiological parameters. Adm = administration.
IM = intramuscular.
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5.3. Citicoline Eye Drops in Glaucoma
To promote patient adherence and compliance to neuroprotective treatment, citicoline was also
recently made available as eye solution. The results from an experimental study demonstrated that
the molecule is traceable in the vitreous when administered topically in solution with benzalkonium
chloride and hyaluronic acid [78].
In this study the right eyes of five CD1 mice were treated with two drops per day for three
days of citicoline 1% and 2%. At the end of the treatment, the vitreous was analyzed using liquid
chromatography and spectrometry mass (LC-MS/MS). Citicoline was detected in the vitreous and
systemic absorption was also noted when the higher concentration was used (2%).
The second phase of this study was clinical, in order to determine if topical citicoline is able
to delay glaucoma progression, considering visual field indices and electrofunctional tests. Patients
were randomized in two groups, the first (16 patients) treated with citicoline eye drops plus ocular
hypotensive therapy for two months and one month of washout and the second (18 patients) treated
only with ocular hypotensive treatment for three months. Individual eyes of patients treated with
citicoline eye drops showed positive improvement that was not statistically significant in the entire
group. RGC function improved up to 30 days after the washout as shown by PERG parameters while
VEP and retino-cortical time improvement regressed after 30 days of washout. No minor or serious
adverse events were reported. No significant modifications of the IOP were recorded during the study.
Authors concluded that citicoline eye drops seems to have a neuroprotective effect that is independent
of pressure-lowering effect due to any hypotensive drops.
Recently, Parisi et al. [79] reported additional results of a prospective, randomized study on the
retinal function and the neural conduction after treatment with citicoline eye drops in patients with
open-angle glaucoma. One group of patients was treated with topical citicoline 3 drops/day in addition
to the topical hypotensive treatment with beta-blockers for four months followed by a two-month
washout period. The other group of patients was treated only with beta-blocker monotherapy for the
whole study (six months). The electrophysiological examination was performed at the baseline and
after four and six month of follow-up. The results of the present study confirmed that after treatment
with citicoline eye drops a significant improvement in PERG and VEP parameters was recorded. In
particular, the shortening of VEP P100 implicit times was correlated significantly with the increase of
PERG P50-N95 amplitudes. Furthermore, a significant correlation was found between the values of
the PERG amplitude at the baseline and relative differences suggesting that patients who had greater
benefits from citicoline eye drops treatment were those that displayed the worst retinal function at
baseline. After washout PERG and VEP values were similar to baseline levels, while patients treated
exclusively with beta-blocker did not show significant changes of PERG and VEP values during the
whole follow-up. Moreover, the improvement of the electrophysiological indices was found to correlate
with the improvement of visual field mean deviation (patients treated with citicoline eye drops in
addition to beta-blockers showed a positive mean progression rate of +0.56 dB while patients treated
only with beta-blockers had a mean progression rate of ´0.24 dB). None of the patients enrolled in the
study reported any ocular side effect or changes in clinical parameters (IOP and visual acuity).
6. Comments and Future Perspectives
Despite the lack of studies on experimental optic nerve damage obtained by means of acute
elevation of IOP, it has been validated that citicoline is able to protect RGC from apoptosis
in glutamate-induced excitotoxicity animal models and after partial optic nerve crush [63–66].
Furthermore, wishing to test a neuroprotective agent among patients who are already maximally
treated with hypotensive drugs, it might be less effective to test them in an IOP generated model.
In glaucoma management, the neuroprotection staircase has three main steps: to protect still
undamaged axons and ganglion cells, to rescue minimally damaged axons and ganglion cells and to
regenerate damaged axons and ganglion cells. In this scenario it may be hypothesized that citicoline
may act in the second step. In particular, it might act in the window between dysfunction and death
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of RGC [80]. Animal models clearly demonstrate that RGC death occurs only at the late stages of
the disease: axon transport slows first, axon severing is observed as second, and RGC death occurs
later [81]. Thus the window between dysfunction and death provides a space for therapies inducing
an increase of retinal elements functioning (neuroenhancement) to take effect and citicoline may play
this role in the short-term period of treatment.
RGC dysfunction versus death cannot be distinguished by current visual field testing or optic
nerve structural measurement, while PERG is able to demonstrate reversible dysfunction after acute
pressure lowering in glaucoma patients [82].
The scientific literature on the role of citicoline in glaucoma management is growing and published
studies differ in terms of populations’ characteristics (e.g., spectrum of visual field defect), outcome
measures (most focused on electrophysiological parameters), length, administration, dosage and
schedule of treatment. Despite of these differences, the available studies are consistent in indicating
that the use of citicoline is associated with positive effects on the visual function. Furthermore, all the
studies mentioned have not reported any adverse effects among patients enrolled confirming that this
molecule is safe and can be used for long-term treatment.
7. Conclusions
The ideal neuroprotection study design is not easy to be realized due to the natural history of
glaucoma itself [83]. This disease has a long, slow course with variable worsening rates among patients
and high outcome measurement variability.
In the future, randomized clinical trials with large population and outcomes related to the patients’
quality of life (such as differential retinal sensitivity as measured by standard achromatic perimetry)
are also needed to obtain a dose-response relation, and to increase the chances of therapeutic success.
The morphological parameters by means of optical coherence tomography (i.e., retinal nerve fiber layer,
or ganglion cell complex thickness) should also be investigated to detect the clinical effect of citicoline.
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